EUVIMEDEUVIMED entdecken
Crossref

Sodium Cantharidinate Enhances Cisplatin Sensitivity in Cervical Cancer via PTPN1-Mediated Inhibition of the PI3K/AKT Pathway

Sara Lindholm, Karin Berg

Pharmaceutical Sciences and Drug Design · 2025

DOI: 10.51847/1hgehtnb9j ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Sciences and Drug Design, 2025. Verfasst von Sara Lindholm und 1 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium cantharidinate (SC) has demonstrated efficacy in treating lung cancer in China, yet its effects in cervical cancer (CC)—a major cause of female reproductive cancer mortality—remain largely unexplored. This study investigates SC’s anti-cancer activity in CC and explores the molecular mechanisms involved. DDP-resistant Caski-1 and ME180 cervical cancer cell lines were established and treated with SC to assess its impact on cell proliferation. Potential molecular targets of SC were predicted

Zitieren

APA

Lindholm, S., & Berg, K. (2025). Sodium Cantharidinate Enhances Cisplatin Sensitivity in Cervical Cancer via PTPN1-Mediated Inhibition of the PI3K/AKT Pathway. Pharmaceutical Sciences and Drug Design. https://doi.org/10.51847/1hgehtnb9j

Vancouver

Lindholm S, Berg K. Sodium Cantharidinate Enhances Cisplatin Sensitivity in Cervical Cancer via PTPN1-Mediated Inhibition of the PI3K/AKT Pathway. Pharmaceutical Sciences and Drug Design. 2025. doi:10.51847/1hgehtnb9j

BibTeX
@article{Lindholm2025,
  author = {Lindholm, Sara and Berg, Karin},
  title = {Sodium Cantharidinate Enhances Cisplatin Sensitivity in Cervical Cancer via PTPN1-Mediated Inhibition of the PI3K/AKT Pathway},
  journal = {Pharmaceutical Sciences and Drug Design},
  year = {2025},
  doi = {10.51847/1hgehtnb9j}
}
Kostenlos starten →